Skip to content
Explore the Longevity Puptides food-bowl spray collection. View formula details and availability updates →

Where Science Meets Love

Research Library · Restored edition

Dog Peptide & Pet Peptide Research Library

You deserve more than a promising headline when you're learning about your dog's health. Explore checked studies on BPC-157, TB-500, GHK-Cu, Epitalon, CBD and canine longevity—with the actual findings, the animals or people studied, and links to the original sources.

18

Checked source records

5

Canine clinical trials

6

Preclinical / laboratory experiments

1

Regulatory guidance entry

This restored library keeps the original compound-by-compound focus while correcting source mismatches and overclaims. It is a selected reading list, not a claim to cover every paper. Study results below are not evidence that a finished Puptides spray works, is safe or reaches the same exposure. No entry provides a dose or a care plan for your dog.

Original evidence comparison · Source-reviewed November 3, 2026

Six studies. Different questions.

What has actually been studied when you search for peptides for dogs? Start with GHK-Cu and TB-500, then compare the molecule, species, administration route and measured endpoint together. These six original studies examine wound collagen, tendon mechanics, blood concentrations and cartilage scores. None tested a finished Longevity Puptides food-bowl spray.

How to read these results

Study 1 · GHK-Cu context — tripeptide-copper complex as named in the canine abstract

Effect of locally injected medications on healing of pad wounds in dogs

Species / sample
Dogs — 12 mature English Pointers
Study type
Controlled experimental wound study; random allocation is not established in the accessible abstract
Administration route
Local intralesional injection into experimentally created paw-pad wounds
Measured endpoint / finding
Type-I collagen: copper-complex wounds contained more than saline controls at day 6 and significantly more than the other wound groups at day 14. Healing rate and hydroxyproline were also measured; the abstract's strongest first-week result for those measures concerned the immunostimulant, not the copper complex.
Limits and source access
Small induced-wound experiment. The primary abstract calls the test material a tripeptide-copper complex, not the retail spray. This is not GHK-only evidence, food-route exposure, healthy skin or coat research, or finished-product safety/efficacy evidence. Verification is at primary-abstract level; the publisher extraction did not expose the article text.
Finished Longevity Puptides spray tested?
No

Related catalog formula, not product studied: Skin & Shine — GHK-Cu

Study 2 · GHK-Cu

Effects of topical copper tripeptide complex on wound healing in an irradiated rat model

Species / sample
Sprague-Dawley rats — 13 test and 10 control animals in the reported image analysis
Study type
Controlled preclinical irradiated-flap experiment
Administration route
Topical GHK-Cu gel on surgically created dorsal flaps after irradiation
Measured endpoint / finding
No significant difference from control ointment in flap ischemia, blood-vessel number or area, or VEGF expression under the prespecified P < .01 threshold.
Limits and source access
An irradiated rat wound model, not canine skin or coat research. The ischemic-area comparison had P = .011, which does not meet the paper's P < .01 threshold; do not call it statistically significant harm or benefit. No food-route or finished-spray testing. Verification is at primary-abstract level.
Finished Longevity Puptides spray tested?
No

Related catalog formula, not product studied: Skin & Shine — GHK-Cu

Study 3 · Paper-labeled TB-500, BPC-157, and their combination — TB-500 fragment identity not confirmed by this paper

Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study

Species / sample
32 young male Sprague-Dawley rats — 8 per group; 4 tendons per group for each analysis stream
Study type
Randomized exploratory preclinical tendon transection-and-repair experiment; coded mechanical testing and blinded histopathology
Administration route
Intraperitoneal research injections following surgical Achilles tendon repair
Measured endpoint / finding
Only the paper-labeled TB-500 arm significantly exceeded control for maximum load to failure in adjusted pairwise comparisons. Selected tissue scores also differed. The combination did not show added benefit over either single-agent arm.
Limits and source access
One early assessment, small endpoint samples, no functional recovery assessment or prospective power calculation. Surgery and treatment administration were unblinded. The paper calls TB-500 synthetic thymosin beta-4 and names a supplier/catalog code but does not establish sequence, length, or batch characterization in its reported methods. Do not treat this as verified evidence for the catalog's TB-500 fragment, as proof of a head-to-head winner, or as a finished combination-spray trial. Verified from publisher full text.
Finished Longevity Puptides spray tested?
No

Related catalog formula, not product studied: Recovery Ranger — TB-500 + BPC-157

Study 4 · Full-length thymosin beta-4 and a seven-amino-acid actin-binding motif — related-molecule context, not a verified TB-500 product

The actin binding site on thymosin beta4 promotes angiogenesis

Species / sample
Human umbilical-vein endothelial cells and chick aortic-arch preparations; no dogs
Study type
Primary in-vitro and ex-vivo mechanism experiment with natural peptide, proteolytic fragments, and synthetic peptides
Administration route
Direct exposure in cell-migration/adhesion and vessel-sprouting assays; no administration to a dog
Measured endpoint / finding
Full-length thymosin beta-4 and its seven-amino-acid actin-binding motif showed similar activity in the reported migration and sprouting assays; peptides missing part of that motif were inactive.
Limits and source access
The full-length molecule is 43 amino acids. Assay activity of a particular motif does not establish that any material sold or cataloged as TB-500 has the same sequence, modification, exposure, safety, or effect. Not a canine recovery experiment or a finished-product study. Keep this row labeled related-molecule context and do not map it to a product. Verification is at primary-abstract level.
Finished Longevity Puptides spray tested?
No

Related-molecule mechanism context only. No catalog formula is mapped to this study.

Study 5 · BPC-157

Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs

Species / sample
6 beagle dogs in the canine arm; separate rat experiments
Study type
Preclinical pharmacokinetic study — blood concentration over time, not a clinical efficacy trial
Administration route
Intravenous and intramuscular BPC-157 in the canine arm
Measured endpoint / finding
The intact peptide peaked rapidly after intramuscular administration and had an elimination half-life under 30 minutes in the tested canine conditions. Separate rat work assessed distribution, metabolism, and excretion.
Limits and source access
Small canine injection study. Pharmacokinetics describes drug handling, not healing, digestion, mobility, or long-term safety. No TB-500 combination, oral ingestion, food-contact stability, or finished-spray trial. Injection bioavailability cannot be transferred to food-bowl use. Verified from publisher full text.
Finished Longevity Puptides spray tested?
No

Related catalog formula, not product studied: Belly Balance — BPC-157

Study 6 · AOD9604, with separate hyaluronic-acid and combination research arms

Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model

Species / sample
32 mature New Zealand white rabbits — 8 per group
Study type
Randomized preclinical collagenase-induced knee osteoarthritis experiment; blinded cartilage grading
Administration route
Intra-articular injection directly into rabbit knee joints
Measured endpoint / finding
Gross cartilage-damage and histopathology scores were lower with AOD9604 than saline. The AOD9604 plus hyaluronic-acid group scored lower than either single-agent group; AOD9604 alone did not differ significantly from hyaluronic acid alone on those scores.
Limits and source access
Small induced-disease rabbit model with a joint-injection route, not canine food exposure. The findings do not establish cartilage regeneration, joint relief, or movement effects from a dog spray. Hyaluronic acid is a study comparator/co-intervention, not an approved Flex & Fetch ingredient. The paper contains inconsistent induction quantities between sections; no experimental quantities are reproduced here. Verified from publisher full text; the PubMed extraction was incomplete.
Finished Longevity Puptides spray tested?
No

Related catalog formula, not product studied: Flex & Fetch — AOD-9604

Read the comparison before choosing a product page.

GHK-Cu: the canine copper-complex experiment used local injections into created paw-pad wounds. Its collagen finding is not healthy-skin or coat evidence. The rat GHK-Cu study found no significant difference at its prespecified threshold. Keeping that null result visible matters.

TB-500: the rat tendon paper names a material called TB-500 but does not establish its sequence, length or batch characterization. It therefore cannot confirm a match to the catalog fragment. A significant comparison against control is not proof that one peptide beat another; the combination showed no added benefit. The full-length thymosin beta-4 and motif study is related-molecule assay evidence, not a canine or finished-product trial.

BPC-157 and AOD9604: the beagle study measured how an injected ingredient moved through the body; it did not establish digestion or recovery. The rabbit study used knee-joint injections. Hyaluronic acid was a research co-intervention, not a Flex & Fetch ingredient.

This is a selected comparison, not a comprehensive literature review or a ranking of sprays. Three sources were checked through publisher full text and three at primary-abstract level, as noted in each entry. Source review is editorial, not clinical or veterinary review. These findings are context for veterinarian-managed discussion, not directions to start, stop or replace care.

What the studies tell us so far

BPC-157: drug handling is not healing

The six-beagle study measured how injected BPC-157 moved through the body. It did not test recovery from an injury. A separate systematic review found 35 preclinical studies and only one small human clinical report in its search period.

BPC-157 evidence review

TB-500 and thymosin beta-4: check the material

Do not assume these names identify an identical molecule or formulation. In the rat tendon comparison below, combining BPC-157 with TB-500 did not add benefit. A human thymosin beta-4 eye-drop trial missed both primary endpoints despite some favorable secondary findings.

Human eye-drop trial

GHK-Cu: collagen findings have narrow limits

A canine experiment found differences in collagen in created paw-pad wounds after local copper-tripeptide injections. That is useful wound biology, but it does not establish that oral GHK-Cu improves a dog's coat or that a food-applied spray heals wounds.

Canine pad-wound experiment

Epitalon: longer telomeres are not longer life

The original mouse lifespan paper found no change in mean lifespan or total tumor incidence. A later cell study measured telomere changes, including in cancer cells. Neither finding establishes more healthy years for a dog. Epitalon is not an ingredient in the ten Longevity Puptides sprays.

Original mouse lifespan studyEpitalon for dogs: evidence and limits

CBD: canine trials, not a universal result

Small controlled dog trials have measured pain scores and seizure frequency. Some findings are encouraging, but important comparisons were negative and adverse effects occurred. CBD is not a peptide, and evidence for one oil does not transfer to every product.

Canine epilepsy trial

Canine longevity: compare actual outcomes

The lifetime feeding study measured survival. The rapamycin trials measured heart-function changes over much shorter periods, with differing results. A heart measurement, telomere assay or owner impression should not be retold as proof of longer life.

Lifetime canine feeding study

Original sources, plain English

Search the research library

Start with a topic or choose Dogs to see the canine entries. The species sections remain separate even when all filters are open. Each card tells you what was compared, what was measured and where the result stops.

Showing 18 of 18 source records

Dogs (9)

Studies involving dogs, plus a clearly labeled review of canine clinical literature. Experimental wound models and drug-handling studies are not pet-dog treatment trials.

BPC-157Pharmacokinetic studyDrug handling

Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs

Frontiers in Pharmacology · 2022

Species / system:
Beagle dogs; separate rat experiments
Sample:
6 beagles in the canine experiments

What was compared: Intravenous versus intramuscular research administration; single and repeated exposure.

What they found: The intact peptide's elimination half-life was under 30 minutes. The canine arm measured blood concentrations after injection; the rat experiments also examined distribution, metabolism and excretion.

What this can—and cannot—tell you about your dog: Blood concentration is not a healing outcome. This paper did not test oral use, a food-bowl spray, cruciate injury recovery or long-term safety in pet dogs.

CBDCanine clinical trialOsteoarthritis / mobility

Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs

Frontiers in Veterinary Science · 2018

Species / system:
Client-owned dogs with osteoarthritis
Sample:
22 recruited; 16 completed and analyzed

What was compared: Randomized, blinded crossover comparison of a CBD-rich oil and placebo oil, with four-week treatment periods.

What they found: Owner-reported pain and activity scores improved from baseline during CBD treatment at weeks 2 and 4. Some veterinary pain comparisons favored CBD, but lameness and weight-bearing measures did not improve. Alkaline phosphatase, a blood enzyme, increased.

What this can—and cannot—tell you about your dog: A small trial with several subjective outcomes and dogs continuing some existing care. It does not show cartilage repair, establish a response deadline or test every CBD formulation.

CBDCanine clinical trialEpilepsy

Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy

Journal of the American Veterinary Medical Association · 2019

Species / system:
Dogs with drug-resistant idiopathic epilepsy
Sample:
26 enrolled; 9 CBD and 7 placebo dogs analyzed

What was compared: CBD-infused oil versus placebo for 12 weeks, added to existing antiepileptic treatment.

What they found: The CBD group had a median 33% reduction in seizure frequency compared with placebo. The proportion achieving at least a 50% reduction was similar between groups. Two CBD dogs withdrew with ataxia, or unsteady movement, and alkaline phosphatase increased.

What this can—and cannot—tell you about your dog: Substantial exclusions and a small analyzed sample limit certainty. The finding does not justify replacing seizure medication or promising a particular dog's response.

CBDCanine clinical trialTolerability

Tolerability of long-term cannabidiol supplementation to healthy adult dogs

Journal of Veterinary Internal Medicine · 2024 issue; online 2023

Species / system:
Healthy adult beagles
Sample:
18 dogs; 6 per group

What was compared: Random assignment to vehicle control or two CBD exposure levels for 36 weeks.

What they found: CBD-exposed groups had increased alkaline phosphatase activity. The higher-exposure group had more soft feces. The authors did not find evidence of liver damage in their measured data, but recommended liver-function monitoring during chronic use.

What this can—and cannot—tell you about your dog: Healthy beagles do not represent every pet dog, disease or drug combination. This is tolerability evidence for the tested material, not a blanket claim that CBD is safe.

GHK-CuPreclinical experimentWound healing / collagen

Effect of locally injected medications on healing of pad wounds in dogs

American Journal of Veterinary Research · 1996

Species / system:
Mature English Pointers
Sample:
12 dogs

What was compared: Locally injected tripeptide-copper complex, an immunostimulant or saline in experimentally created pad wounds.

What they found: Copper-tripeptide-treated wounds contained more type-I collagen than controls at day 6; at day 14, the amount was significantly greater than in the other wound groups.

What this can—and cannot—tell you about your dog: This is an experimental wound study using local injections. It does not establish oral GHK-Cu effects, coat improvements or food-bowl-spray results.

Canine longevityNutritionControlled feeding studyLifespan / body condition

Effects of diet restriction on life span and age-related changes in dogs

Journal of the American Veterinary Medical Association · 2002

Species / system:
Labrador Retrievers
Sample:
48 dogs in paired groups

What was compared: Lifetime paired feeding, with one dog in each pair receiving less food than its pair-mate from puppyhood.

What they found: The lower-intake group had longer median lifespan, lower body fat and later onset of clinical signs of chronic disease than the comparison group.

What this can—and cannot—tell you about your dog: A controlled, single-breed lifetime study is not a feeding plan for your dog. Nutritional adequacy, age and body condition matter; do not copy the experimental restriction at home.

Canine longevityRapamycinCanine clinical trialCardiac aging

A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs

GeroScience · 2017

Species / system:
Healthy middle-aged companion dogs
Sample:
24 dogs

What was compared: Placebo versus rapamycin over 10 weeks, with cardiac ultrasound and clinical testing.

What they found: Cardiac ultrasound suggested improvement in some measures of heart contraction and filling. The study did not find clinical side effects relative to placebo during the short observation period.

What this can—and cannot—tell you about your dog: The study measured heart-function signals, not longer life. Its small sample and short duration cannot establish lifelong safety or survival benefit.

Canine longevityRapamycinCanine clinical trialCardiac aging

A masked, placebo-controlled, randomized clinical trial evaluating safety and the effect on cardiac function of low-dose rapamycin in 17 healthy client-owned dogs

Frontiers in Veterinary Science · 2023

Species / system:
Healthy client-owned dogs aged 6–10 years
Sample:
17 dogs

What was compared: Rapamycin versus placebo for six months; evaluations continued to 12 months.

What they found: There were no statistically significant differences in cardiac ultrasound measures between groups at six or 12 months. No clinically significant adverse events were reported; owners in the rapamycin group more often reported perceived positive changes.

What this can—and cannot—tell you about your dog: Owner impressions did not establish improved cardiac function or lifespan. A different schedule and small cohort mean this is not an exact replication of the 2017 trial.

Canine healthNarrative reviewOsteoarthritis / treatment comparisons

Advances in the pharmaceutical treatment options for canine osteoarthritis

Journal of Small Animal Practice · 2022

Species / system:
Canine clinical literature
Sample:
Review; no single enrolled sample

What was compared: Evidence across anti-inflammatory drugs, newer drug classes, adjunctive analgesics and regenerative approaches.

What they found: The review describes a growing range of options and emphasizes multimodal care, including weight management and physiotherapy alongside medicines. It calls for larger randomized trials to strengthen the evidence.

What this can—and cannot—tell you about your dog: It is not a head-to-head trial or proof that experimental peptides should replace established treatment. Different approaches have different evidence and risks.

Rodents (3)

Rat and mouse experiments can reveal biological signals. They cannot tell us that a dog will have the same result.

BPC-157TB-500 / thymosin beta-4Preclinical experimentTendon repair

Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study

Joint Diseases and Related Surgery · 2026

Species / system:
Male Sprague-Dawley rats
Sample:
32 rats; 8 per group; 4 tendons per group for each analysis stream

What was compared: Control, BPC-157, TB-500 or their combination after surgical Achilles tendon transection and repair; injected research administration.

What they found: Only the TB-500 arm had a statistically significant advantage over control in maximum load to failure after adjusted pairwise comparisons. Some tissue measures differed, but the combination did not add benefit over the individual arms.

What this can—and cannot—tell you about your dog: Young rats with surgically repaired tendons are not dogs with cruciate disease. Small endpoint samples, one four-week assessment and incomplete material characterization limit broader conclusions.

GHK-CuPreclinical experimentWound healing

The effect of topical tripeptide-copper complex on healing of ischemic open wounds

Veterinary Surgery · 2003

Species / system:
Adult male Sprague-Dawley rats
Sample:
24 rats

What was compared: Topical copper-tripeptide gel, its vehicle or no treatment on experimentally created wounds with reduced blood supply.

What they found: By day 13, wound area had decreased by 64.5% with the copper-tripeptide gel, 45.6% with its vehicle and 28.2% with no treatment. Several inflammatory and tissue-remodeling measurements were lower than control.

What this can—and cannot—tell you about your dog: These are topical rat wound results, not evidence for a canine oral formulation, healthy skin or coat growth.

EpitalonPreclinical experimentLifespan / aging markers

Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice

Biogerontology · 2003

Species / system:
Female Swiss-derived SHR mice
Sample:
108 mice; 54 per group

What was compared: Injected Epitalon versus saline from three months of age until natural death.

What they found: Mean lifespan and total spontaneous tumor incidence did not change. Maximum lifespan and survival of the last 10% of mice increased; some reproductive and chromosome measures also differed.

What this can—and cannot—tell you about your dog: A result among the longest-lived mice is not the same as extending average life. This study cannot establish canine longevity or cancer prevention.

Humans (1)

Clinical research in people is kept separate from canine evidence, even when a related peptide name appears.

TB-500 / thymosin beta-4Human clinical trialDry eye

Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment model

Clinical Ophthalmology · 2015

Species / system:
People with moderate to severe dry eye
Sample:
72 people randomized

What was compared: Thymosin beta-4 eye drops versus placebo over 28 days.

What they found: Neither primary endpoint—ocular discomfort or inferior corneal staining at the specified visit—differed significantly. Some secondary measures of discomfort and corneal staining favored the experimental solution.

What this can—and cannot—tell you about your dog: This tested a defined thymosin beta-4 eye-drop formulation, not a canine TB-500 product. Secondary findings should not hide the negative primary outcomes.

Cells & tissues (2)

Experiments outside a living animal. Human cells or donated tissue do not make a study a human clinical trial.

EpitalonLaboratory experimentCellular aging

Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity

Biogerontology · 2025; figures corrected November 2025

Species / system:
Human normal epithelial and fibroblast cells; breast-cancer cell lines
Sample:
Cell experiments, not enrolled people or dogs

What was compared: Epitalon-exposed versus untreated cell cultures.

What they found: Telomere length increased in normal cells alongside telomerase-related changes. Cancer cells also showed telomere extension, involving alternative lengthening of telomeres, a different maintenance mechanism.

What this can—and cannot—tell you about your dog: Telomere changes in a dish are not evidence of longer or healthier life. The cancer-cell findings also make a simple anti-aging interpretation inappropriate. A published correction replaces Figures 1–3.

BPC-157Laboratory experimentGut signaling / nerve cells

Cytoprotective Mechanism of the Novel Gastric Peptide BPC157 in Gastrointestinal Tract and Cultured Enteric Neurons and Glial Cells

Neuroscience Bulletin · 2019 issue; online 2018

Species / system:
Rat intestinal cells and tissue; human intestinal tissue samples
Sample:
Rat cell cultures from 4 rats; tissue sample counts vary by experiment

What was compared: BPC-157 exposure versus control in isolated intestinal strips and cell cultures.

What they found: The peptide reduced contraction in isolated intestinal strips. Cultured rat intestinal neurons had greater survival at four weeks, while serotonin-release results differed between rat and human samples.

What this can—and cannot—tell you about your dog: This is tissue and cell work, not a canine inflammatory bowel disease trial. It cannot establish digestive symptom relief, intestinal healing or oral effects in dogs.

Mixed species (2)

Multi-species toxicology and evidence synthesis. Read the individual species and design rather than treating every included result as canine evidence.

BPC-157Toxicology studyToxicology

Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds

Regulatory Toxicology and Pharmacology · 2020

Species / system:
Mice, rats, rabbits and dogs
Sample:
Animal totals not stated in the accessible abstract

What was compared: BPC-157 versus control across several preclinical toxicity tests.

What they found: The authors reported no serious toxicity under the tested conditions. Repeated canine exposure produced a creatinine decrease at the highest tested level; the animals recovered after withdrawal. Local irritation was described as mild.

What this can—and cannot—tell you about your dog: A finite toxicology program does not mean zero risk at any exposure. It does not establish long-term safety, benefit in a sick dog or safety of a different finished formulation.

BPC-157Systematic reviewMusculoskeletal evidence

Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review

HSS Journal · 2025

Species / system:
Predominantly preclinical models; one human clinical report
Sample:
36 included studies: 35 preclinical and 1 clinical

What was compared: Review of literature through June 3, 2024, rather than a new treatment comparison.

What they found: Preclinical injury models reported favorable functional, structural or mechanical outcomes. The single human report was retrospective and small; the review found no clinical safety data.

What this can—and cannot—tell you about your dog: The review does not turn rodent injury results into proven canine care. Its search cutoff matters, and its one human report was not a randomized trial.

Regulatory (1)

Official guidance answers labeling and regulatory questions. It is not a clinical trial or an approval of the products on this site.

RegulationRegulatory guidanceFood and drug claims

Animal Food Labeling and Pet Food Claims

U.S. Food and Drug Administration · Page current March 2, 2026

Species / system:
U.S. animal-food regulation
Sample:
Not a study; no participants

What was compared: Regulatory explanation, not an efficacy comparison.

What they found: FDA explains that expressed or implied disease-treatment claims, and certain non-food structure or function claims, can indicate intended use as a new animal drug. Such claims require the animal-drug approval process to appear on the label.

What this can—and cannot—tell you about your dog: A published ingredient paper is not FDA approval of a pet product. This guidance does not certify any Puptides ingredient, formulation or delivery method.

A wider scientific reading shelf

Find the papers behind the ingredients.

Browse 45 distinct additional sources across all ten sprays. This shelf includes exact-ingredient experiments, mechanism reviews and delivery research. It is separate from the checked canine and clinical records above: a paper’s relationship to an ingredient is not a trial of the finished spray.

Showing 45 of 45 additional sources

mechanism review

Oxytocin as an Indicator of Psychological and Social Well-Being in Domesticated Animals: A Critical Review

Rault JL, van den Munkhof M, Buisman-Pijlman FTA. Oxytocin as an Indicator of Psychological and Social Well-Being in Domesticated Animals: A Critical Review. Frontiers in Psychology. 2017;8:1521. doi:10.3389/fpsyg.2017.01521.

Species and research route: Review of domesticated-animal literature, including dogs; discusses endogenous oxytocin sampling and experimental delivery across studies rather than one standardized route.

What researchers found: The review reports that oxytocin research in domesticated animals is often conducted in socially relevant settings, with limited non-social controls and inconsistent control of emotional valence or arousal. It concludes that oxytocin actions are shaped by environmental and social context, evidence linking oxytocin directly to psychological states is limited, and it is premature to treat oxytocin as a validated welfare indicator because findings are few, discrepant, and methodologically non-standardized.

Relevance and study scope

This gives necessary context for reading the existing canine intranasal oxytocin studies: a change in social behavior under a particular test does not automatically mean generalized calm, and oxytocin biology should not be interpreted independently of the social setting and outcome measure.

This is a critical narrative review rather than a trial of Calm Companion. It does not test Selank, Semax, the three-ingredient combination, food exposure, or a finished spray, and its conclusions do not establish efficacy or safety in an individual dog.

Read the original paper

exact ingredient study

Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission

Volkova A, Shadrina M, Kolomin T, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology. 2016;7:31. doi:10.3389/fphar.2016.00031.

Species and research route: 30 male Wistar rats; single intranasal Selank at 300 micrograms/kg; frontal-cortex gene expression measured at 1 and 3 hours.

What researchers found: The investigators measured 84 neurotransmission-related genes and found significant mRNA changes in 45 genes at 1 hour and 22 genes at 3 hours after Selank or GABA exposure. Selank and GABA changes were positively correlated at 1 hour, but the patterns were not identical; the authors interpreted the results as consistent with a possible allosteric influence on GABAergic signaling, alongside effects involving other neurotransmitter systems. The paper itself states that further work is needed to define the mechanism across models.

Relevance and study scope

This adds molecular context for why Selank is studied in relation to inhibitory neurotransmission and stress-related behavior, without treating a rat gene-expression experiment as proof of a calming outcome in dogs.

The study used rats, not dogs, and measured short-term cortical mRNA changes rather than behavior, clinical anxiety, or welfare. The frontal-cortex samples were pooled by group and time point, the route was intranasal rather than food-based, and the experiment did not test oxytocin, Semax, the combined formula, or a finished spray.

Read the original paper

exact ingredient study

The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis

Medvedeva EV, Dmitrieva VG, Povarova OV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15:228. doi:10.1186/1471-2164-15-228.

Species and research route: Adult male Wistar rats with permanent middle-cerebral-artery occlusion; repeated intraperitoneal Semax at 100 micrograms/kg at 15 minutes, 1, 4, and 8 hours; ischemic cortex transcriptomes assessed at 3 and 24 hours.

What researchers found: In this focal-ischemia model, Semax altered expression of 96 genes at 3 hours and 68 genes at 24 hours using the study's stated cutoff. More than half of the altered genes at the reported immune-response time point were related to immune processes, including immunoglobulin and chemokine genes; vascular-related genes also changed, including genes associated with endothelial development, cell migration, hematopoiesis, and vasculogenesis. The authors describe these as possible contributors to neuroprotection in ischemia, while noting that many altered genes have uncertain functional significance and that the mechanism remains complex.

Relevance and study scope

This paper shows that Semax research includes broad immune and vascular gene responses in a defined brain-injury model, which helps distinguish molecular and disease-model findings from claims about ordinary canine calm or social behavior.

This is an acute rat ischemia experiment using repeated intraperitoneal injections, not a dog study and not a stress or social-behavior study. Gene-expression changes do not establish a beneficial behavioral outcome, oral or food-route absorption, finished-spray stability, safety, or an effect of Semax combined with Selank and oxytocin.

Read the original paper

mechanism review

Delta-sleep-inducing peptide (DSIP): an update

Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): an update. Peptides. 1986;7(6):1165-1187. doi:10.1016/0196-9781(86)90148-8. PMID:3550726.

Species and research route: Cross-species literature review covering animal and human studies; routes varied across the reviewed literature and were not a single DSIP administration experiment.

What researchers found: This review described additional reports of sleep-related and extra-sleep effects, distribution and immunochemical findings, and proposed links to adrenergic transmission. It stated that DSIP’s physiological functions and a possible adrenergic mechanism still required establishment rather than presenting a settled mechanism.

Relevance and study scope

It is useful broader reading because it places the older sleep claims, tissue-distribution observations, and mechanistic hypotheses in historical context while making clear that the biology was unresolved. That caution helps prevent an older animal or human result from being treated as proof of a predictable canine response.

This is a 1986 narrative review rather than a new controlled canine study, and its conclusions reflect the literature available at that time. It does not test oral or food delivery, the finished spray, or an owner-facing sleep outcome in dogs.

Read the original paper

exact ingredient study

Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study

Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992;26(4):193-197. doi:10.1159/000118919. PMID:1299794.

Species and research route: 16 adults with chronic insomnia; double-blind matched-pairs parallel groups; intravenous DSIP at 25 nmol/kg on three afternoons, compared with glucose placebo.

What researchers found: Polysomnography showed higher sleep efficiency and shorter sleep latency with DSIP than placebo, and one subjective tiredness measure decreased within the DSIP group. The authors judged the statistically significant effects weak, noted that part of the difference could reflect an incidental placebo-group change, found no change in other measures including subjective sleep quality, and concluded that short-term DSIP was unlikely to provide major therapeutic benefit for chronic insomnia.

Relevance and study scope

This is direct human DSIP evidence and is valuable chiefly because it includes a controlled comparison and a restrained conclusion rather than a simple positive claim. It shows that even intravenous exposure produced limited and mixed findings, which is important context when considering extrapolation to a dog-food route.

The sample was very small, the participants were humans with chronic insomnia, and the route was intravenous rather than oral or food-applied. It did not study dogs, a metered spray, palatability, product stability, or routine evening use.

Read the original paper

exact ingredient study

Delta sleep-inducing peptide modulates the stimulation of rat pineal N-acetyltransferase activity by involving the alpha 1-adrenergic receptor

Graf MV, Schoenenberger GA. Delta sleep-inducing peptide modulates the stimulation of rat pineal N-acetyltransferase activity by involving the alpha 1-adrenergic receptor. Journal of Neurochemistry. 1987;48(4):1252-1257. doi:10.1111/j.1471-4159.1987.tb05654.x. PMID:3029331.

Species and research route: In vitro rat pineal preparation; DSIP at 20-300 nM and phosphorylated DSIP analogue tested with norepinephrine, prazosin, and propranolol.

What researchers found: DSIP at 20-300 nM significantly enhanced norepinephrine-induced pineal N-acetyltransferase activity in the rat preparation, and a phosphorylated analogue showed a similar effect. Prazosin eliminated the enhancement, while propranolol reduced norepinephrine stimulation that remained increased by the peptide; the authors therefore proposed modulation involving alpha-1 adrenergic signaling.

Relevance and study scope

This gives a concrete laboratory mechanism behind one historical DSIP hypothesis: interaction with adrenergic signaling in a pineal enzyme system. It helps explain what researchers mean by a proposed mechanism without turning a cell-free or tissue preparation into evidence of sleep improvement in a dog.

The work used rat pineal tissue outside the animal and included a phosphorylated DSIP analogue, so it does not establish the same pathway in dogs or intact animals. It did not measure sleep, behavior, oral absorption, food-matrix exposure, or finished-spray performance.

Read the original paper

delivery research

Saturable mechanism for delta sleep-inducing peptide (DSIP) at the blood-brain barrier of the vascularly perfused guinea pig brain

Zlokovic BV, Susic VT, Davson H, Begley DJ, Jankov RM, Mitrovic DM, Lipovac MN. Saturable mechanism for delta sleep-inducing peptide (DSIP) at the blood-brain barrier of the vascularly perfused guinea pig brain. Peptides. 1989;10(2):249-254. doi:10.1016/0196-9781(89)90026-0. PMID:2547200.

Species and research route: Vascularly perfused in situ guinea-pig forebrain; luminal exposure to radiolabeled DSIP, with unlabelled DSIP, L-tryptophan, and vasopressin as competitors or comparators.

What researchers found: Radiolabeled DSIP entered perfused guinea-pig forebrain regions with measurable transfer constants. Excess unlabelled DSIP inhibited uptake toward mannitol-like values, and the data were interpreted as evidence for a high-affinity saturable transport process with binding at brain capillary membranes; L-tryptophan also inhibited transfer.

Relevance and study scope

This is useful delivery biology because it addresses a specific question behind CNS peptide research: whether DSIP movement at a blood-brain interface may involve a saturable process rather than simple unrestricted diffusion. It can help an owner understand why systemic exposure, transport, and brain availability are separate questions.

The experiment used an isolated perfused guinea-pig brain, not a living dog receiving DSIP by mouth or in food. It does not establish intestinal absorption, intact-peptide delivery, a dose for dogs, or a sleep or safety outcome for the finished spray.

Read the original paper

exact ingredient study

Some pharmacological effects of delta-sleep-inducing peptide (DSIP)

Scherschlicht R, Aeppli L, Polc P, Haefely W. Some pharmacological effects of delta-sleep-inducing peptide (DSIP). European Neurology. 1984;23(5):346-352. doi:10.1159/000115712. PMID:6548967.

Species and research route: Rabbits and cats under normal or disturbed-sleep conditions, plus morphine-dependent mice; intravenous and subcutaneous synthetic DSIP injections.

What researchers found: In rabbits, intravenous 25 micrograms/kg and subcutaneous 1 mg/kg DSIP increased spindle-dominated light non-REM sleep and prevented stress-associated hyposomnia. In cats, the tested doses preferentially increased REM sleep and abolished morphine’s sleep-suppressant effect; in morphine-dependent mice, selected doses reduced naloxone-induced withdrawal jumping. The investigators reported indications of bell-shaped dose-response relationships in most settings.

Relevance and study scope

This primary study shows that DSIP findings varied by species, sleep state, endpoint, and dose, rather than producing one uniform sleep effect. That variability is directly relevant when interpreting the ingredient’s historical pharmacology without projecting it onto dogs or a food-bowl spray.

These were injected-animal experiments involving rabbits, cats, and mice, including drug-withdrawal models; none involved dogs, oral or food delivery, or the finished product. The dose-response observations and sleep-stage results cannot establish routine canine outcomes or safety.

Read the original paper

mechanism review

Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications

Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current Neuropharmacology. 2016;14(8):857-865. doi:10.2174/1570159X13666160502153022.

Species and research route: Review of mainly rodent and other laboratory studies; included gastrointestinal injury models and varied experimental administration routes rather than a canine food route.

What researchers found: The review describes BPC-157 as the 15-amino-acid sequence GEPPPGKPADDAGLV and summarizes reported effects in experimental gastrointestinal lesions, intestinal anastomoses, fistulas, and tissue injury. It discusses nitric-oxide signaling, endothelial protection, and EGR-1/NAB2 and FAK-paxillin/JAK-2 pathways as proposed explanations, not established clinical mechanisms.

Relevance and study scope

It gives useful biological context for why BPC-157 is discussed in gastrointestinal and tissue-healing research, while keeping the ingredient separate from TB-500 and full-length thymosin beta-4.

This is a narrative review that emphasizes positive preclinical findings and does not establish a finished-spray result, canine benefit, oral absorption, or long-term safety. Its summarized experiments are heterogeneous and mostly use small laboratory animals.

Read the original paper

exact ingredient study

MODULATORY EFFECT OF GASTRIC PENTADECAPEPTIDE BPC 157 ON ANGIOGENESIS IN MUSCLE AND TENDON HEALING

Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. MODULATORY EFFECT OF GASTRIC PENTADECAPEPTIDE BPC 157 ON ANGIOGENESIS IN MUSCLE AND TENDON HEALING. Journal of Physiology and Pharmacology. 2009;60(Suppl 7):191-196.

Species and research route: Human endothelial-cell angiogenesis assay and male Wistar rats with muscle-crush, quadriceps-transection, or Achilles-tendon-transection injuries; BPC-157 10 micrograms/kg intraperitoneally in rats.

What researchers found: BPC-157 did not significantly increase tubule branching in the cell-culture assay at the tested concentrations. In the rat injury models, treated tissue showed an earlier or stronger pattern of VEGF, CD34, and FVIII immunostaining, which the authors interpreted as an in-vivo angiogenic or angiomodulatory response during healing.

Relevance and study scope

The negative cell result is important: the paper does not show a simple direct angiogenic effect. Its rat findings provide a specific example of the proposed vascular-healing mechanism for exact BPC-157, separate from evidence about TB-500.

The work used small rat groups, induced injuries, intraperitoneal dosing, and tissue markers rather than canine outcomes or food exposure. Marker changes cannot establish that a food-bowl spray reaches injured tissue or improves an individual dog's recovery.

Read the original paper

mechanism review

Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Mechanisms of Action and Probable Toxicity

Józwiak M, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Mechanisms of Action and Probable Toxicity. Pharmaceuticals. 2025;18(2):185. doi:10.3390/ph18020185.

Species and research route: Critical review of predominantly rat and mouse studies using varied routes; it also discusses limited dog and other preclinical material.

What researchers found: The review summarizes proposed BPC-157 interactions with nitric-oxide, vascular, inflammatory, and repair pathways but stresses that the mechanism, metabolic enzymes, binding interactions, and adverse effects remain incompletely defined. It notes that most studies are small-animal experiments with limited routes and that completed clinical efficacy studies are absent.

Relevance and study scope

This newer review adds a needed counterweight to highly positive mechanistic summaries: it helps an owner distinguish a plausible research mechanism from demonstrated safety or efficacy for Recovery Ranger.

It is a secondary review, not a new canine efficacy study, and its conclusions cannot determine the behavior of a particular formulation in food. The authors specifically call for more systematic toxicity, pharmacokinetic, interaction, and mechanism work.

Read the original paper

related molecule context

The actin binding site on thymosin beta4 promotes angiogenesis

Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB Journal. 2003;17(14):2103-2105. doi:10.1096/fj.03-0121fje. PMID:14500546.

Species and research route: Human umbilical-vein endothelial-cell migration and adhesion assays plus chick aortic-ring sprouting; natural full-length thymosin beta-4, proteolytic fragments, and synthetic peptides tested in vitro or ex vivo.

What researchers found: The paper identifies full-length thymosin beta-4 as a 43-amino-acid, approximately 5-kDa G-actin-sequestering peptide. A seven-amino-acid actin-binding motif reproduced angiogenic activity near 50 nM in endothelial-cell migration and chick aortic-ring assays, while peptides missing part of that motif were inactive; soluble actin inhibited adhesion and sprouting.

Relevance and study scope

It explains a concrete cellular mechanism often invoked for thymosin beta-4 tissue research and makes the molecule distinction explicit. These findings should not be reassigned to an incompletely specified TB-500 material or to BPC-157.

The experiments were cell-based or ex vivo and did not test dogs, oral or food delivery, a finished formula, or functional recovery. A fragment's activity in these assays does not establish that a commercial TB-500 preparation has the same sequence, exposure, or effect.

Read the original paper

related molecule context

Progress on the Function and Application of Thymosin β4

Xing Y, et al. Progress on the Function and Application of Thymosin β4. Frontiers in Cell and Developmental Biology. 2021;9:767395. doi:10.3389/fcell.2021.767395.

Species and research route: Review spanning cell culture, rodent and other mammalian models, and selected human studies with topical, local, systemic, or experimental administration; not a TB-500 dog study.

What researchers found: The review describes full-length thymosin beta-4 as 43 amino acids and summarizes work in which thymosin beta-4 or its fragments affected endothelial-cell migration, capillary-like structures, VEGF-associated signaling, proliferation, and apoptosis-related measures. It also notes that different sequence regions have been assigned different activities.

Relevance and study scope

This is useful background for reading thymosin literature without treating every beta-4 fragment or derivative as TB-500. It supports discussing mechanism as broader molecule context, not as direct evidence for Recovery Ranger.

The review combines heterogeneous models, routes, sequences, and outcomes, so it cannot identify the sequence or predict exposure of the finished ingredient. It does not establish canine efficacy, food-route stability, dosing, or safety for TB-500 plus BPC-157.

Read the original paper

delivery research

Oral delivery of protein and peptide drugs: from noninvasive to invasive delivery strategies

Chen G, et al. Oral delivery of protein and peptide drugs: from noninvasive to invasive delivery strategies. Theranostics. 2022;12(3):1419-1443. doi:10.7150/thno.66931.

Species and research route: General review of oral protein and peptide delivery research, including in-vitro, animal, and translational formulation studies; not specific to BPC-157, TB-500, dogs, or a food-bowl spray.

What researchers found: The review explains that oral peptides face salivary, gastric, and intestinal proteases, mucus and epithelial barriers, enzymatic metabolism, efflux, and post-absorptive clearance. It describes nanoparticles, lipid systems, hydrogels, absorption enhancers, and pH-sensitive enteric coatings as investigated approaches, while noting limited drug loading, aggregation, manufacturing difficulty, instability, possible cytotoxicity, and the need for more translation work.

Relevance and study scope

It gives an evidence-based reason not to infer oral or food-route absorption from injected BPC-157 or thymosin studies. It also helps an owner understand why a delivery claim requires direct stability, exposure, and formulation testing rather than a mechanism analogy.

This is broad delivery literature and does not test either Recovery Ranger ingredient or the finished spray. Improvements reported for other peptides, carriers, or enteric systems cannot be transferred to this product without direct experiments.

Read the original paper

exact ingredient study

Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment

Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. International Journal of Obesity and Related Metabolic Disorders. 2001;25(10):1442-1449. doi:10.1038/sj.ijo.0801740.

Species and research route: Obese ob/ob mice and lean C57BL/6J mice; AOD9604 was delivered for 14 days with mini-osmotic pumps. Separate BaF-BO3 cells expressing the human growth-hormone receptor were used for binding and proliferation assays.

What researchers found: In obese mice, AOD9604 reduced body-weight gain, increased fat oxidation, and increased plasma glycerol, an index of lipolysis. Unlike full-length human growth hormone, it did not cause hyperglycaemia or reduce insulin secretion in this experiment. AOD9604 did not compete for the human growth-hormone receptor and did not induce receptor-associated cell proliferation in the tested cell system.

Relevance and study scope

This is useful mechanistic context for separating AOD-9604 from full-length growth hormone: the reported metabolic readouts occurred without the tested classical receptor interaction or cell-proliferation response. It is also closer to the ingredient than studies of unrelated peptides, while still being preclinical.

The intervention was in mice using implanted pumps, not dogs, oral food exposure, or a metered spray. The cell assay used a human receptor system and cannot establish the receptor biology of canine tissues or identify the finished product's active route. Mouse weight and lipid findings do not establish a movement or joint outcome in dogs.

Read the original paper

exact ingredient study

Detection and in vitro metabolism of AOD9604

Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D. Drug Testing and Analysis. 2015;7(1):31-38. doi:10.1002/dta.1715.

Species and research route: AOD9604 was incubated in serum and urine in vitro; the study also validated extraction and mass-spectrometry detection in human urine and quantified metabolites in serum.

What researchers found: The authors describe AOD9604 as the C-terminal human-growth-hormone fragment 177-191 with an added N-terminal tyrosine. They identified six potential metabolites after serum and urine incubation; one serum metabolite, CRSVEGSCG, was more stable than the parent peptide or the other detected metabolites. The work validated a urine method with a reported 50 pg/mL detection limit.

Relevance and study scope

This paper helps explain that measuring the parent peptide is not the same as demonstrating intact exposure: AOD-9604 underwent detectable breakdown in the tested biological matrices. It adds analytical and metabolism context when considering any oral or food-contact route.

This was an analytical validation and in-vitro metabolism study, not a dosing study, absorption study, canine study, or efficacy trial. It does not show how much intact AOD-9604 would remain after contact with dog food, nor does it establish safety, stability, or an owner-facing outcome for the spray.

Read the original paper

delivery research

Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health

Moré MI, Kenley D. Journal of Endocrinology and Metabolism. 2014;4(3):64-77. doi:10.14740/jem213w.

Species and research route: Nonclinical program including oral gavage in rats for 6 months and cynomolgus monkeys for 9 months, intravenous dosing in rats, and oral or intravenous AOD9604 in pigs for pharmacokinetic sampling; in-vitro genotoxicity assays used bacterial and CHO-cell systems.

What researchers found: The report found no mutagenic signal in its Ames, chromosome-aberration, or bone-marrow micronucleus assays and reported no major treatment-related toxicological concern in the described chronic oral rat and monkey studies. In the pig pharmacokinetic experiment, orally administered AOD9604 was detected and showed rapid degradation; the report also described whole-body distribution of radiolabeled material in rats after oral or intravenous dosing.

Relevance and study scope

This is the most directly useful additional source for understanding that oral exposure and degradation were investigated in laboratory species, while also showing that route-specific pharmacokinetics matter. It provides broader context for interpreting an oral or food-applied concept without converting animal toxicology into a dog-product conclusion.

The paper is a sponsor-linked nonclinical report and its oral studies used gavage, not a dog-food spray. Detection of material after oral dosing does not establish intact-peptide absorption, effective exposure, palatability, product stability, or efficacy. The described species, doses, formulations, and study conditions do not validate the finished spray in dogs.

Read the original paper

exact ingredient study

Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans

Stier H, Vos E, Kenley D. Journal of Endocrinology and Metabolism. 2013;3(1-2):7-15. doi:10.4021/jem157w.

Species and research route: Six randomized, double-blind, placebo-controlled human trials; the program included oral and intravenous clinical studies, with blood testing for IGF-1, glucose-tolerance measures, and anti-AOD9604 antibodies.

What researchers found: The authors' pooled clinical-trial safety summary reported no change in serum IGF-1, no adverse effect on carbohydrate metabolism in the reported oral-glucose-tolerance testing, and no anti-AOD9604 antibodies in the patients selected for antibody testing. No study reported a withdrawal or serious adverse event attributed to intake in the summarized trials.

Relevance and study scope

This source adds human evidence about selected biomarkers and tolerability, and it supports keeping AOD-9604 distinct from full-length growth hormone when discussing IGF-1 and glucose-related endpoints. It also supplies an important negative result: the clinical safety synthesis did not establish a movement benefit.

This is a summary of human trials, not a canine study and not an evaluation of a food-bowl spray. The abstract does not provide a canine dose, formulation, route, long-term dog safety dataset, or movement endpoint. Absence of a reported signal in these selected trials cannot guarantee safety for an individual dog or for this finished product.

Read the original paper

mechanism review

Obesity Pharmacotherapy: Current Perspectives and Future Directions

Misra M. Current Cardiology Reviews. 2013;9(1):33-54. doi:10.2174/157340313805076322.

Species and research route: Narrative review of obesity-pharmacotherapy research across human clinical studies and animal or cellular models; the AOD-9604 discussion summarizes oral human development and earlier preclinical work rather than presenting a new experiment.

What researchers found: The review describes AOD-9604 as an orally active analogue of the lipolytic region of human growth hormone and reports mixed human development: an earlier 12-week study was summarized as showing greater average weight loss than placebo, whereas a later 24-week trial in 536 people did not find significant weight loss. The review therefore presents AOD-9604 as an investigational candidate with inconsistent clinical efficacy rather than an established obesity treatment.

Relevance and study scope

This broader review is useful for placing the animal metabolic findings beside the human evidence and for preserving the negative or mixed clinical result. It helps prevent a mouse fat-metabolism result from being presented as a predictable outcome for a dog or as evidence for movement support.

It is a 2013 narrative review and does not test AOD-9604, dogs, joint function, food delivery, or the finished spray. Its clinical-trial summaries are secondary reporting, and the review's obesity focus does not establish any canine movement, mobility, safety, or disease-prevention effect.

Read the original paper

mechanism review

Cytoprotective Mechanism of the Novel Gastric Peptide BPC157 in Gastrointestinal Tract and Cultured Enteric Neurons and Glial Cells

Wang XY, Qu M, Duan R, et al. Neuroscience Bulletin. 2019;35(1):167-170. doi:10.1007/s12264-018-0269-8. PMID:30116973.

Species and research route: Ex vivo human jejunum, ileum, and colon strips; rat stomach, jejunum, ileum, and colon strips; cultured rat ileal and colonic enteric neurons and enteric glial cells; direct bath or culture-medium exposure to BPC-157, not a live-animal treatment route.

What researchers found: In isolated rat and human intestinal preparations, 40 micromol/L BPC-157 reduced the amplitude of spontaneous muscle contractions. It also lowered measured enteric 5-HT in rat ileal and colonic samples, while the human 5-HT result was inconsistent and did not show the same reduction in samples from patients with colonic cancer. In rat cell cultures, 100 micromol/L BPC-157 increased four-week survival of ileal enteric neurons from 19.23% in controls to 31.69% and increased enteric-glial proliferation from 147.98% to 159.95% of the day-three cell count.

Relevance and study scope

This is useful broader mechanism reading because it connects BPC-157 with enteric serotonin measurements, intestinal motility, enteric neurons, and enteric glia rather than relying only on ulcer-area endpoints. The mixed human tissue findings also show why a laboratory mechanism should not be treated as a uniform digestive effect.

The study used isolated tissues and cultures, not dogs or a food-applied product. Concentrations were direct experimental exposures, and the authors stated that the detailed signaling pathway in enteric neurons and enterocytes still required further investigation; the results do not establish oral absorption, finished-product performance, safety, or a clinical digestive outcome.

Read the original paper

exact ingredient study

Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat

Vuksic T, Zoricic I, Brcic L, et al. Surgery Today. 2007;37(9):768-777. doi:10.1007/s00595-006-3498-9. PMID:17713731.

Species and research route: Rats with surgically created ileoileal anastomoses; BPC-157 10 micrograms/kg, 10 nanograms/kg, or 10 picograms/kg administered intraperitoneally once daily, beginning after surgery and ending 24 hours before assessment.

What researchers found: At the two higher tested doses, the investigators reported improvement across macroscopic, histologic, and biomechanical measures of anastomotic healing. Edema was lower from day one, granulocyte numbers decreased, and from days four or five the study reported less necrosis with more granulation tissue, reticulin, collagen formation, and epithelialization; adhesion formation remained slight and temporary mild obstruction was observed.

Relevance and study scope

This adds a distinct intestinal-surgery model to the existing gastric-ulcer evidence and shows the kinds of tissue-integrity endpoints researchers have used for BPC-157. It may help explain why intestinal repair is a recurring research topic without converting a postoperative rat result into an everyday-digestion claim.

This was a rat surgical-injury experiment with intraperitoneal dosing, not a canine study, routine feeding study, or food-bowl spray. It measured healing of a deliberately created anastomosis rather than normal gastrointestinal function, and it does not establish absorption, dosing, safety, stability, or efficacy for Belly Balance.

Read the original paper

exact ingredient study

Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability

Klicek R, Kolenc D, Suran J, et al. Journal of Physiology and Pharmacology. 2013;64(5):597-612. PMID:24304574.

Species and research route: Wistar rats with intrarectal cysteamine colitis or colon-colon anastomosis; BPC-157 given intraperitoneally at 10 micrograms/kg or 10 nanograms/kg once daily, or orally in drinking water at 0.16 micrograms/mL or 0.16 nanograms/mL; the paper also used an intragastric route in a separate cuprizone model.

What researchers found: In the reported experiments, untreated controls did not heal the cysteamine colitis or colon-colon anastomosis, whereas BPC-157 treatment was described as producing efficient healing in both models. The authors tested both intraperitoneal dosing and drinking-water exposure, and assessed colon injury and anastomosis endpoints alongside histologic and functional measures; the same paper also reported less cuprizone-related neural damage and better motor measures, which are separate from the GI experiments.

Relevance and study scope

This is one of the more directly relevant broader readings for gastrointestinal research because it includes chemically induced colitis, a colon surgical model, and an oral drinking-water exposure rather than only injection. It helps distinguish a controlled injury model from a claim about a healthy dog’s ordinary digestion.

All intervention findings were in rats, with induced disease or surgery and laboratory administration. The drinking-water route is not equivalent to a metered spray applied to dog food, and the study did not test dogs, the finished product, palatability, stability in food, or clinical digestive outcomes.

Read the original paper

mechanism review

Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats—A Review

Bajramagic S, Sever M, Rasic F, et al. Pharmaceuticals. 2024;17(8):1081. doi:10.3390/ph17081081. PMID:39204186.

Species and research route: Review of preclinical rat studies involving intestinal and other gastrointestinal anastomoses, fistulas, short-bowel and colitis models; routes across the reviewed studies include intraperitoneal, oral/drinking-water, intragastric, and local administration.

What researchers found: The review organizes reported BPC-157 findings across esophagogastric, colocolonic, jejunoileal, and ileoileal anastomoses, as well as several fistula and intestinal-adaptation models. It presents recurring discussions of epithelial and endothelial integrity, nitric-oxide and prostaglandin systems, and collateral vascular responses as possible explanatory themes, while the underlying evidence remains predominantly rat preclinical work.

Relevance and study scope

This provides a broader map of the gastrointestinal literature and clarifies that the research question is often surgical tissue repair or induced injury, not routine digestive wellness. It is useful for understanding how proposed mechanisms are assembled across multiple models and routes.

This is a narrative review rather than a new controlled trial, and its conclusions depend largely on a preclinical literature concentrated in rats and on studies from related research programs. It does not establish canine efficacy, oral bioavailability from food, finished-spray safety or stability, a dose, or prevention or treatment of disease in an individual dog.

Read the original paper

mechanism review

Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data

Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. doi:10.3390/ijms19071987.

Species and research route: Review of human-cell, animal, and tissue-repair literature; routes and models varied and were not standardized to oral or food delivery.

What researchers found: The review describes GHK/GHK-Cu research involving collagen, elastin, glycosaminoglycan, fibroblast, angiogenesis, inflammatory, and gene-expression measurements. It emphasizes that the literature spans multiple biological systems and proposed pathways rather than one demonstrated skin or coat outcome.

Relevance and study scope

It explains why GHK-Cu is studied in connective-tissue remodeling and places collagen-related findings alongside broader cellular observations. It also helps separate mechanistic and preclinical evidence from evidence about a finished canine spray.

This is a narrative review, not a new controlled canine study. It includes heterogeneous studies, some involving GHK rather than the copper complex, and does not establish oral absorption, product stability, safety, or a skin or coat benefit in dogs.

Read the original paper

delivery research

A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials

Najafi N, Maatouk H, Vardanyan KG, Vartanian KB, Agrawal DK. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials. Archives of Internal Medicine Research. 2026;9(3):269-293. doi:10.26502/aimr.0255.

Species and research route: Systematic review of in vitro, ex vivo, rodent, non-rodent, and human studies, with emphasis on topical and microneedle delivery; no canine food-bowl route was tested.

What researchers found: The review retained 64 records and reports that the human literature remains small and heterogeneous. It identifies a major gap: no adequately powered published human randomized trial had evaluated GHK-Cu delivered by a microneedle platform, while study concentrations, topical formulations, outcomes, and methods varied substantially; it also notes that most human studies were small and often incompletely reported.

Relevance and study scope

This is useful for understanding delivery as a separate scientific question from ingredient mechanism. It supports cautious interpretation of topical and enhanced-delivery results and makes clear that those findings cannot establish behavior in a meal-applied spray.

The review is recent and its conclusions depend on the quality and reporting of the included studies; it is not a canine efficacy or safety trial. Microneedle, cream, ex vivo skin, and cell studies do not demonstrate that GHK-Cu survives food contact, reaches canine skin, or produces a finished-product outcome.

Read the original paper

exact ingredient study

The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures

Siméon A, Emonard H, Hornebeck W, Maquart FX. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sciences. 2000;67(18):2257-2265. doi:10.1016/S0024-3205(00)00803-1. PMID:11045606.

Species and research route: Cultured dermal fibroblasts; direct in-vitro exposure to GHK-Cu, copper ions, or GHK without a live-animal route.

What researchers found: GHK-Cu increased matrix metalloproteinase-2 in fibroblast-conditioned media and increased MMP-2 messenger RNA. It also increased secretion of tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2; copper ions reproduced the effect, whereas GHK alone did not under the study conditions.

Relevance and study scope

The findings add a specific extracellular-matrix remodeling mechanism rather than treating collagen synthesis as the only relevant endpoint. The paired MMP and inhibitor findings help explain why remodeling biology is more complex than simply increasing one structural protein.

This was a cell-culture experiment with no dog, no intact skin, no oral exposure, and no coat endpoint. Changes in MMP and TIMP measurements do not show improved healing, absorption, safety, or efficacy of a food-bowl spray.

Read the original paper

exact ingredient study

Expression and activation of matrix metalloproteinases in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+

Siméon A, Monier F, Emonard H, Gillery P, Birembaut P, Hornebeck W, Maquart FX. Expression and activation of matrix metalloproteinases in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. Journal of Investigative Dermatology. 1999;112(6):957-964. doi:10.1046/j.1523-1747.1999.00606.x. PMID:10383745.

Species and research route: Male Sprague-Dawley rats with subcutaneous wound chambers; serial local injections of 2 mg GHK-Cu or saline.

What researchers found: In this wound-chamber model, GHK-Cu did not alter interstitial collagenase activity. It increased pro-MMP-2 and activated MMP-2 during later healing stages, while the study described stage-specific expression of MMP-2 and MMP-9 across the healing process.

Relevance and study scope

The paper is useful because it shows a time-dependent remodeling result and includes a negative finding, rather than implying that every wound enzyme endpoint moved in the same direction. It gives context for how GHK-Cu may be investigated in tissue repair without converting rat injection data into canine coat claims.

This was a rat wound model using local injections, not a dog study and not oral or food delivery. The enzyme changes are surrogate mechanistic measurements; they do not establish a visible benefit, general skin improvement, dose equivalence, or finished-spray performance.

Read the original paper

exact ingredient study

Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin

Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Archives of Facial Plastic Surgery. 2006;8(4):252-259. doi:10.1001/archfaci.8.4.252. PMID:16847171.

Species and research route: Randomized human topical study; 13 patients completing post-CO2-laser resurfacing regimens with or without a GHK-Cu skin-care product.

What researchers found: Blinded evaluators and computer analysis found no statistically significant difference in the speed or resolution of erythema. Objective assessments also found no significant between-group improvement in wrinkles or overall skin quality, although questionnaire-based satisfaction favored the GHK-Cu group.

Relevance and study scope

This small randomized study adds an important mixed result: subjective satisfaction differed, while the main objective skin measures did not. It helps prevent broad claims that topical GHK-Cu consistently improves visible skin outcomes and reinforces that human topical evidence is not canine oral evidence.

Only 13 patients completed the study, and the intervention followed laser resurfacing in human skin rather than routine use in dogs. It did not test ingestion, food contact, coat or hair endpoints, long-term safety, or the finished spray.

Read the original paper

exact ingredient study

Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog

Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006;91(12):4792-4797. doi:10.1210/jc.2006-1702. PMID:17018654.

Species and research route: Healthy men aged 20–40 years; single subcutaneous CJC-1295 injection at 60 or 90 micrograms/kg; overnight serial blood sampling before and one week after dosing.

What researchers found: CJC-1295 increased overall GH and IGF-1 secretion while preserving the pulsatile pattern of GH release. The reported change was driven mainly by a 7.5-fold increase in trough GH; mean GH rose 46% and IGF-1 rose 45%, with no significant difference between the two tested doses.

Relevance and study scope

This adds detail to the existing human CJC-1295 pharmacology evidence by showing that a long-acting GHRH analogue did not simply replace pulses with a flat signal under these conditions. It helps explain why GH and IGF-1 measurements are mechanistic endpoints rather than proof of improved vitality, movement, or lifespan in dogs.

The study involved a small, short human clinical experiment using subcutaneous injection of CJC-1295 alone. It did not test dogs, Ipamorelin, the exact combination, food exposure, a spray, or owner-facing outcomes; its findings cannot establish canine efficacy or safety.

Read the original paper

related molecule context

Structural basis for activation of the growth hormone-releasing hormone receptor

Zhou F, Zhang H, Cong Z, et al. Nat Commun. 2020;11(1):5205. doi:10.1038/s41467-020-18945-0. PMID:33060564.

Species and research route: Human GHRH receptor studied by cryo-electron microscopy with endogenous GHRH and stimulatory G protein; receptor mutagenesis and cAMP assays in HEK293T cells; no administered animal or human route.

What researchers found: The study resolved a 2.6-angstrom structure of human GHRH bound to GHRHR and stimulatory G protein. It showed that GHRH makes an extensive interaction network across extracellular loops, transmembrane helices, and the receptor extracellular domain, and that selected disease-associated receptor mutations impair signaling in cellular assays.

Relevance and study scope

This provides receptor-level context for CJC-1295 as a GHRH-related signaling agent: receptor activation depends on defined molecular contacts and downstream G-protein signaling, not on a generic claim that any peptide raises growth hormone. It also illustrates why results from human receptor structure and cell assays should not be treated as a direct test of Prime Pup in dogs.

The paper studied endogenous human GHRH and human receptor constructs, not CJC-1295, Ipamorelin, canine receptors, a food route, or a finished product. Structural and cell-signaling findings explain mechanism but do not establish absorption, clinical benefit, or safety in dogs.

Read the original paper

delivery research

Approaches for Enhancing Oral Bioavailability of Peptides and Proteins

Renukuntla J, Vadlapudi AD, Patel A, Boddu SHS, Mitra AK. Int J Pharm. 2013;447(1-2):75-93. doi:10.1016/j.ijpharm.2013.02.030. PMID:23428883.

Species and research route: Review of oral peptide and protein delivery barriers and enhancement technologies, including GI, cell, membrane, and preclinical transport studies; no single species or administered route applies to the review as a whole.

What researchers found: The review states that oral peptide and protein bioavailability is commonly very low because of gastrointestinal enzymatic degradation and poor epithelial permeability, and it discusses protective carriers, nanoparticles, absorption enhancers, enzyme inhibitors, and targeting strategies. It emphasizes that a viable system must preserve molecular integrity, release material at an absorption site, and retain it long enough for uptake; many approaches had limited success at the time of publication.

Relevance and study scope

This complementary review helps an owner understand why injection pharmacokinetics cannot be transferred to a meal-applied spray. It also makes clear that an oral delivery claim requires evidence about intact peptide stability and transport, not merely evidence that the unmodified ingredient has activity after injection.

The review is not specific to CJC-1295, Ipamorelin, dogs, or this product, and its literature predates some newer oral peptide technologies. Its general barriers and cautions do not quantify Prime Pup exposure or predict an individual dog's response.

Read the original paper

exact ingredient study

Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus

Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. J Exp Pharmacol. 2012;4:149-155. doi:10.2147/JEP.S35396. PMID:27186127.

Species and research route: Adult male Sprague-Dawley rats with surgically induced postoperative ileus; intravenous Ipamorelin at 0.014 or 0.14 micromoles/kg; ex vivo rat gastric-fundus contractility assays.

What researchers found: In rats whose abdominal surgery and intestinal manipulation delayed gastric emptying, intravenous Ipamorelin reduced the radiolabeled meal remaining in the stomach and improved small-intestinal transit; the higher tested dose produced the stronger transit response. In isolated gastric tissue from the same model, Ipamorelin reversed impaired acetylcholine- and electrically stimulated contractile responses, supporting a ghrelin-receptor and enteric-neural mechanism under the experimental conditions.

Relevance and study scope

This paper adds a non-GH endpoint for Ipamorelin and shows that ghrelin-receptor biology can affect gastrointestinal motility in a specific injury and surgery model. It is useful mechanistic context, but it should not be read as evidence that Prime Pup changes digestion or motility in healthy mature dogs.

The experiment used small groups of rats, intravenous dosing, a surgically induced postoperative-ileus model, and short-term measurements. It did not test dogs, CJC-1295, the exact combination, oral or food delivery, a finished spray, chronic exposure, or routine digestive outcomes.

Read the original paper

exact ingredient study

The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress

Kim KH, Son JM, Benayoun BA, Lee C. Cell Metabolism. 2018;28(3):516-524. doi:10.1016/j.cmet.2018.06.008.

Species and research route: In vitro human-cell and molecular experiments; exogenous fluorescent MOTS-c exposure, genetic expression and localization assays; no animal dosing route.

What researchers found: The study found that endogenous MOTS-c was mainly extra-nuclear with some mitochondrial association at baseline, while fluorescent MOTS-c could show mitochondrial and nuclear localization within 30 minutes of treatment. Mutation experiments implicated the hydrophobic 8YIFY11 region in nuclear entry, whereas changing the basic 13RKLR16 sequence did not block entry; nuclear-loss mutants still reduced cellular oxygen consumption, suggesting that not all effects require nuclear localization.

Relevance and study scope

This is direct native-MOTS-c mechanistic evidence that makes the mitochondrial-to-nuclear signaling idea more concrete and shows that sequence-dependent protein interactions may matter. It helps explain why a change in a cellular endpoint cannot automatically be read as a whole-animal vitality or cognition result.

The work used cultured cells, fluorescent or genetically expressed constructs, and molecular endpoints rather than dogs, oral administration, food exposure, or a finished spray. It does not establish extracellular stability, gastrointestinal absorption, product behavior, or an owner-observable outcome.

Read the original paper

exact ingredient study

MOTS-c interacts synergistically with exercise intervention to regulate PGC-1α expression, attenuate insulin resistance and enhance glucose metabolism in mice via AMPK signaling pathway

Yang B, Yu Q, Chang B, et al. Biochimica et Biophysica Acta - Molecular Basis of Disease. 2021;1867(6):166126. doi:10.1016/j.bbadis.2021.166126.

Species and research route: C2C12 mouse myotubes in vitro and male C57BL mice with high-fat-diet-induced obesity; recombinant MOTS-c supplementation and treadmill-training intervention, with the abstract not specifying a canine or oral route.

What researchers found: In C2C12 myotubes, AMPK inhibition reduced PGC-1α and MOTS-c expression, PGC-1α knockdown reduced MOTS-c expression, and PGC-1α overexpression or recombinant MOTS-c increased MOTS-c expression. In high-fat-diet mice, treadmill training increased muscle MOTS-c, PGC-1α, GLUT4, and phosphorylation of AMPK and ACC; the authors interpreted the findings as evidence of an AMPK/PGC-1α relationship and possible interaction between exercise and MOTS-c.

Relevance and study scope

This paper adds depth to the metabolic-signaling pathway by connecting native MOTS-c measurements with AMPK, PGC-1α, GLUT4, and exercise in a mouse model. It is useful for understanding a proposed cellular-energy mechanism, not for treating exercise-associated measurements as proof of a finished product effect.

The study used mouse cells and mice, not dogs, and its interventions were recombinant peptide supplementation or treadmill training rather than a food-bowl spray. It measured signaling, insulin resistance, and glucose-metabolism endpoints; it did not test cognition, daily vitality, oral absorption, finished-product stability, or long-term safety.

Read the original paper

exact ingredient study

The Mitochondrial-Derived Peptide (MOTS-c) Interacted with Nrf2 to Defend the Antioxidant System to Protect Dopaminergic Neurons Against Rotenone Exposure

Xiao J, Zhang Q, Shan Y, et al. Molecular Neurobiology. 2023;60(10):5915-5930. doi:10.1007/s12035-023-03443-3.

Species and research route: PC12 rat-derived cells exposed to rotenone and rats exposed to rotenone; exogenous MOTS-c pretreatment, with cellular localization and antioxidant-pathway measurements; the PubMed abstract does not specify the animal administration route.

What researchers found: In rotenone-exposed PC12 cells, more MOTS-c moved from mitochondria toward the nucleus, where the authors reported direct interaction with Nrf2 and regulation of HO-1 and NQO1. In cell and rat experiments, MOTS-c pretreatment reduced measured mitochondrial dysfunction and oxidative stress, preserved selected tyrosine-hydroxylase, PSD95, and synaptophysin signals, and partly normalized Nrf2, HO-1, NQO1, and Keap1 changes in striatum.

Relevance and study scope

This study gives a specific example of the proposed mitochondrial-to-nuclear mechanism and links native MOTS-c to an antioxidant-response pathway in a neurotoxicology model. It can help an owner understand why mechanistic papers may mention neuronal or oxidative-stress biology without establishing a cognitive benefit in dogs.

The experiments used rat-derived cells and a rotenone injury model in rats, not healthy dogs or a finished spray. Pretreatment in a toxin model is not evidence of prevention, treatment, cognition improvement, or routine vitality; the paper also does not establish oral absorption, food compatibility, stability, or safety for this product.

Read the original paper

mechanism review

MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases

Mohtashami Z, Singh MK, Salimiaghdam N, Ozgul M, Kenney MC. International Journal of Molecular Sciences. 2022;23(19):11991. doi:10.3390/ijms231911991.

Species and research route: Review of human observational work, cell studies, and animal studies using varied experimental exposures; not a new dosing study and not a canine food-route study.

What researchers found: This review describes MOTS-c as a 16-amino-acid peptide encoded by the mitochondrial 12S rRNA region and summarizes reports that metabolic stress can accompany nuclear translocation, AMPK-related signaling, AICAR accumulation, and interactions with stress-response transcription factors including Nrf2/ARE. It also presents age-related and disease-related findings across studies while noting that the detailed entry and action mechanisms remain under investigation.

Relevance and study scope

The review is useful for connecting isolated findings about mitochondrial localization, AMPK, nuclear regulation, aging, and metabolism into one map of the research field. Its broad scope makes the species, route, endpoint, and evidence-quality differences visible rather than allowing them to be collapsed into a single dog claim.

This is a narrative review, not a canine efficacy or pharmacokinetic study. It discusses therapeutic potential but does not demonstrate that native MOTS-c survives food exposure, is absorbed from a spray, reaches a target tissue in dogs, or changes cognition, energy, movement, aging, or disease outcomes in an individual animal.

Read the original paper

mechanism review

MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation

Zheng Y, et al. Frontiers in Endocrinology. 2023;14:1120533. doi:10.3389/fendo.2023.1120533.

Species and research route: Review of cell, rodent, and human observational or experimental literature with varied routes; no new intervention and no canine food-route study.

What researchers found: The review summarizes MOTS-c as a 16-amino-acid mitochondrial-derived peptide and discusses reported links with skeletal-muscle metabolism, insulin sensitivity, exercise, and age-related research. It specifically notes uncertainty about how MOTS-c enters cells without degradation while retaining activity, and it identifies delivery and biosafety as unresolved development problems.

Relevance and study scope

This review is especially helpful for interpreting the gap between a plausible mechanism and a usable intervention: the literature includes promising preclinical signals but still has open questions about cellular uptake, delivery, and translation. It therefore supports a more precise reading of native-MOTS-c papers without treating engineered delivery concepts or rodent findings as evidence for this spray.

The article is a review rather than a dog study and includes heterogeneous evidence with different species, routes, and endpoints. It does not establish finished-spray absorption, stability, safety, dosing, or efficacy, and it cannot turn mouse or cell findings into canine cognition or daily-vitality evidence.

Read the original paper

exact ingredient study

A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation

Falutz J, Allas S, Kotler D, et al. AIDS. 2005;19(12):1279-1287. doi:10.1097/01.aids.0000180099.35146.30. PMID:16052083.

Species and research route: Humans: 61 HIV-infected adults with increased waist circumference and waist-to-hip ratio; randomized, double-blind, placebo-controlled trial; TH9507 (tesamorelin) 1 or 2 mg subcutaneously once daily for 12 weeks.

What researchers found: Tesamorelin produced dose-related increases in IGF-1 of 48% at 1 mg and 65% at 2 mg versus placebo. At 2 mg, trunk fat decreased 9.2% versus a 0.8% increase with placebo, and visceral fat decreased 15.7% within the group, but the visceral-fat comparison versus placebo was not statistically significant. Subcutaneous fat was preserved, lean body mass and the visceral-to-subcutaneous-fat ratio improved, and the 2 mg group had lower triglycerides and a lower cholesterol-to-HDL ratio without a reported glucose increase over 12 weeks.

Relevance and study scope

This is an early controlled human study of the same active ingredient and shows both the endocrine signal and the distinction between a within-group change and a statistically significant placebo comparison. It helps explain why tesamorelin research focuses on visceral rather than general fat measures.

The study used daily subcutaneous injection in a selected HIV-associated abdominal-fat population for only 12 weeks. It did not test dogs, oral or food exposure, a spray, long-term clinical outcomes, or Heart Hero; the authors called for larger and longer studies, and the visceral-fat result was not significant versus placebo.

Read the original paper

exact ingredient study

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension

Falutz J, Potvin D, Mamputu JC, et al. J Acquir Immune Defic Syndr. 2010;53(3):311-322. doi:10.1097/QAI.0b013e3181cbdaff. PMID:20101189.

Species and research route: Humans: 404 HIV-infected adults with antiretroviral-associated abdominal fat accumulation; randomized placebo-controlled trial followed by blinded rerandomization; tesamorelin 2 mg subcutaneously daily for 6 or 12 months.

What researchers found: After six months, visceral adipose tissue decreased 10.9% (21 cm²) with tesamorelin versus 0.6% (1 cm²) with placebo, while trunk fat, waist circumference, and waist-to-hip ratio improved without a change in limb or abdominal subcutaneous fat. IGF-1 increased, and glucose parameters did not change in the reported comparison. Among participants continuing tesamorelin for 12 months, visceral fat reduction was about 18%; participants who switched to placebo rapidly lost the earlier visceral-fat improvement.

Relevance and study scope

This longer controlled study clarifies the duration and reversibility of the best-known tesamorelin body-composition findings. The switch-to-placebo result is particularly useful for understanding that an injected study effect was not shown to persist independently of continued treatment.

Participants were adults with HIV-associated abdominal fat accumulation, not dogs or generally healthy aging animals. The route was subcutaneous injection, not ingestion or application to food, and the endpoints were body-composition, biomarker, and patient-reported measures rather than canine cardiovascular outcomes or finished-spray performance.

Read the original paper

exact ingredient study

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial

Stanley TL, Feldpausch MN, Oh J, et al. JAMA. 2014;312(4):380-389. doi:10.1001/jama.2014.8334. PMID:25038357.

Species and research route: Humans: 50 antiretroviral-treated HIV-infected men and women with abdominal fat accumulation; double-blind randomized placebo-controlled trial; tesamorelin 2 mg subcutaneously daily for 6 months.

What researchers found: Among 48 participants who received study drug, tesamorelin reduced visceral adipose tissue by a mean 34 cm² versus an 8 cm² increase with placebo, for a treatment effect of -42 cm². Liver-fat lipid-to-water percentage also fell by a median 2.0% versus a 0.9% increase with placebo. Fasting glucose rose at two weeks, although six-month fasting and two-hour glucose differences were not statistically significant across time points. The authors described the trial as preliminary and said the clinical importance and long-term consequences required further study.

Relevance and study scope

This adds a directly measured liver-fat endpoint and documents an early glucose signal alongside the six-month results. It supports careful discussion of tesamorelin biology without turning a selected human surrogate-endpoint trial into a claim about heart health or canine disease prevention.

This was a small, preliminary human study in an HIV-associated fat-accumulation population using daily subcutaneous injection. It did not test dogs, oral or food-associated exposure, a metered spray, or cardiovascular events; the liver-fat and visceral-fat findings do not establish clinical benefit for Heart Hero.

Read the original paper

exact ingredient study

Reduction in Visceral Adiposity Is Associated With an Improved Metabolic Profile in HIV-Infected Patients Receiving Tesamorelin

Stanley TL, Falutz J, Marsolais C, et al. Clinical Infectious Diseases. 2012;54(11):1642-1651. doi:10.1093/cid/cis251. PMID:22495074. PMCID:PMC3348954.

Species and research route: Humans: pooled phase III randomized, double-blind studies of HIV-infected adults with abdominal fat accumulation; tesamorelin 2 mg subcutaneously each morning for 26 weeks, with a continued-treatment or switch-to-placebo extension to 52 weeks; responder analysis of 402 tesamorelin-treated participants at 26 weeks and 152 at 52 weeks with paired visceral-fat data.

What researchers found: The prespecified responder threshold was at least an 8% reduction in visceral adipose tissue. At 26 weeks, responders had larger reductions in triglycerides and smaller increases in fasting glucose, insulin, HbA1c, and HOMA-IR than nonresponders; adiponectin increased in responders. At 52 weeks, responders again had lower triglycerides and better glucose-related measures than nonresponders. The paper reports associations between visceral-fat change and metabolic measures; it does not prove that visceral-fat reduction alone caused each metabolic difference.

Relevance and study scope

This paper deepens interpretation of the human evidence by separating participants who did and did not meet a visceral-fat response threshold rather than treating every treated participant as equivalent. It also makes clear that metabolic findings were tied to an analysis of responders and nonresponders, not to a demonstrated dog or cardiovascular outcome.

This was a post hoc analysis of selected participants from two human HIV trials, not a new randomized comparison of responders. It used injected tesamorelin and did not test dogs, oral or food delivery, a spray, or Heart Hero; the associations cannot establish causation or predict an individual animal's response.

Read the original paper

delivery research

Oral delivery of peptide drugs: barriers and developments

Hamman JH, Enslin GM, Kotzé AF. BioDrugs. 2005;19(3):165-177. doi:10.2165/00063030-200519030-00003. PMID:15984901.

Species and research route: Review of oral peptide and protein delivery research across human and animal literature; focuses on gastrointestinal administration, intestinal degradation, mucosal penetration, absorption enhancers, and adapted delivery systems rather than a tesamorelin trial.

What researchers found: The review explains that most peptide drugs remain parenteral because gastrointestinal absorption of intact peptides is inadequate. It identifies presystemic enzymatic degradation and poor intestinal-mucosa penetration as major barriers, and describes approaches including altered peptide physicochemical properties, functional excipients, and specialized delivery systems. It also notes unresolved concerns such as excipient toxicity, person-to-person absorption variability, and manufacturing cost.

Relevance and study scope

Tesamorelin's existing canine evidence uses pulmonary or injected administration, so this review supplies the missing route biology needed to avoid assuming that exposure from those routes transfers to a food-associated route. It helps an owner understand why a food-bowl format would require its own stability, release, absorption, and exposure evidence.

This is a broad delivery review, not a tesamorelin study and not evidence that any particular spray, food matrix, excipient, or formulation overcomes the stated barriers. It does not establish Heart Hero stability, absorption, dosing, safety, or efficacy in dogs.

Read the original paper

delivery research

Oral delivery of proteins and peptides: Challenges, status quo and future perspectives

Zhu Q, Chen Z, Paul PK, Lu Y, Wu W, Qi J. Oral delivery of proteins and peptides: Challenges, status quo and future perspectives. Acta Pharmaceutica Sinica B. 2021;11(8):2416-2448. doi:10.1016/j.apsb.2021.04.001.

Species and research route: Review of oral protein and peptide delivery research across laboratory and pharmaceutical systems; no Cardiogen-specific experiment and no canine finished-product test.

What researchers found: The review describes two central barriers to oral peptide exposure: rapid degradation in changing gastrointestinal pH and enzyme environments, and poor passage through mucus and intestinal epithelium. It surveys approaches such as enteric protection, enzyme inhibitors, permeation enhancers, chemical modification, and nanocarriers; these are specialized delivery strategies, not properties that can be inferred from a simple food-applied spray.

Relevance and study scope

This gives useful mechanistic context for why an injected or ex-vivo result involving a peptide called Cardiogen cannot establish intact oral exposure. It also supports keeping any AEDR transporter or delivery discussion conditional: the review concerns peptide-delivery technologies generally and does not identify the Daily Defense material as AEDR.

This is a broad review rather than a Cardiogen study. Its examples include other peptides, engineered formulations, and non-canine systems, so it does not establish Cardiogen stability, absorption, safety, or efficacy in dogs or in the finished formula.

Read the original paper

delivery research

Impact of gastrointestinal differences in veterinary species on the oral drug solubility, in vivo dissolution, and formulation of veterinary therapeutics

Martinez MN, Papich MG, Fahmy R. Impact of gastrointestinal differences in veterinary species on the oral drug solubility, in vivo dissolution, and formulation of veterinary therapeutics. ADMET & DMPK. 2022;10(1):1-25. doi:10.5599/admet.1140.

Species and research route: Veterinary pharmacokinetic and formulation review covering dogs, cats, and other veterinary species; oral drug administration and gastrointestinal dissolution/solubility considerations.

What researchers found: The review explains that canine body size, intestinal dimensions, transit, gastric and intestinal pH, bile composition, fed state, and other gastrointestinal variables can affect dissolution and oral performance. It notes that canine gastric and intestinal conditions differ from human conditions and that information about fed canine gastrointestinal fluids is limited, making formulation and exposure predictions uncertain.

Relevance and study scope

Because Daily Defense is described as food-associated oral use, this paper helps explain why human or generic peptide-delivery assumptions do not substitute for dog-specific testing. It also makes clear that a dog route question involves the food matrix and canine physiology, not just whether a short sequence has a plausible transporter interaction in a model.

This review is not about Cardiogen, AEDR, ultrashort bioregulator peptides, or the finished spray. It discusses oral veterinary therapeutics broadly and therefore cannot demonstrate gastrointestinal stability, absorption, or a biological outcome for this ingredient.

Read the original paper

mechanism review

Therapeutic peptides: current applications and future directions

Wang L, Wang N, Zhang W, et al. Therapeutic peptides: current applications and future directions. Signal Transduction and Targeted Therapy. 2022;7:48. doi:10.1038/s41392-022-00904-4.

Species and research route: Review of therapeutic-peptide discovery, modification, pharmacology, and delivery across human and experimental systems; no Cardiogen-specific or canine oral trial.

What researchers found: The review states that peptides are generally vulnerable to hydrolysis by digestive enzymes, which is why many peptide medicines are administered by injection. It describes how chemical modification, lipid conjugation, enzyme protection, and permeation enhancers can change stability or delivery, while emphasizing that these strategies concern particular engineered molecules and formulations; for example, oral semaglutide depends on a specific modified peptide and SNAC co-formulation.

Relevance and study scope

This helps distinguish a general peptide mechanism or sequence discussion from evidence about a product’s route and analyte. It is particularly relevant to Cardiogen because the exact formula sequence is unconfirmed: evidence for a different engineered peptide, a different conjugate, or a different delivery system cannot be assigned to Cardiogen or treated as proof of finished-spray performance.

This is a broad review of therapeutic peptides, not a Cardiogen or AEDR primary study. Its examples largely involve human medicines and engineered molecules, so it does not establish native Cardiogen identity, dog pharmacokinetics, gastrointestinal stability, safety, dosing, or efficacy.

Read the original paper

Read the comparison, not just the conclusion

A pain questionnaire, a collagen measurement and survival are different outcomes. Improvement from a starting score is also different from improvement over placebo. Look for both, and notice how many animals finished the study—not just how many enrolled. A four-week study visit is not a promise that a dog will improve by week four.

Reviews summarize existing work; they do not add new treated dogs. Trial registrations describe planned research unless results have been posted. News articles, grant announcements, retailer pages and owner anecdotes are not counted as clinical trials here. The library includes negative findings because they are just as important when you are weighing a hopeful claim.

For a question about your own dog, your veterinarian can weigh the diagnosis, medicines, diet and other details that a study summary cannot. These pages are education, not directions to start, stop or replace care.

Print a one-claim evidence worksheet

Separate from the evidence library

Explore the Puptides collection

If you are looking for the named food-bowl sprays, the collection pages introduce them separately. Research on an ingredient, injection or topical gel does not establish the efficacy, safety or bioavailability of a finished spray. A link here is not a treatment recommendation.

Published by Longevity Puptides

Published: Restored edition — November 2, 2026 · Substantive update: November 4, 2026

Source-checked peptide, CBD and canine longevity education. Individual studies retain their species, formulation and outcome limits. This library is not individual veterinary advice or evidence of finished-product performance.

Editorial standards and corrections